Achieve Life Sciences (NASDAQ:ACHV) Stock Price Up 3.2% – What’s Next?

07 Oct 2026, 17:01 by Danessa Lincoln · The Markets Daily

Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report)’s share price shot up 3.2% during trading on Wednesday. The company traded as high as $7.24 and last traded at $7.2540. 121,677 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 1,355,992 shares. The stock had previously closed at $7.03.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Wednesday, August 19th. Wall Street Zen lowered shares of Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Morgan Stanley initiated coverage on Achieve Life Sciences in a report on Thursday, August 13th. They set an “overweight” rating and a $13.00 price objective for the company. UBS Group reissued a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $18.00 target price on shares of Achieve Life Sciences in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Achieve Life Sciences currently has a consensus rating of “Buy” and an average target price of $15.50.

Read Our Latest Analysis on Achieve Life Sciences

Achieve Life Sciences Stock Performance

The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.87. The company has a market cap of $747.57 million, a PE ratio of -4.69 and a beta of 2.30. The firm’s 50-day simple moving average is $7.52 and its two-hundred day simple moving average is $5.85.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). As a group, research analysts anticipate that Achieve Life Sciences, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Richard Stewart sold 20,626 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total value of $175,114.74. Following the completion of the transaction, the director owned 208,249 shares in the company, valued at $1,768,034.01. This trade represents a 9.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. Frazier Life Sciences Management L.P. purchased a new stake in shares of Achieve Life Sciences in the 2nd quarter valued at $49,725,000. venBio Partners LLC purchased a new position in shares of Achieve Life Sciences in the second quarter valued at approximately $38,623,122. BlackRock Inc. purchased a new stake in shares of Achieve Life Sciences during the second quarter worth approximately $34,426,000. Jupiter Topco LLC acquired a new position in Achieve Life Sciences in the 2nd quarter valued at $17,964,000. Finally, Alyeska Investment Group L.P. purchased a new position in Achieve Life Sciences in the 2nd quarter valued at $12,575,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

About Achieve Life Sciences

(Get Free Report)

Achieve Life Sciences, Inc is a biopharmaceutical company focused on developing and commercializing cytisinicline, a plant-based investigational therapy intended to help adults quit smoking and address nicotine addiction. Cytisinicline is designed to act on nicotinic acetylcholine receptors in the brain, potentially reducing nicotine cravings and withdrawal symptoms while helping limit the satisfaction associated with smoking.